Deep knowledge on 
 small-molecule drugs and 
 the 100,000 global patents 
 covering them 

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: alvimopan

« Back to Dashboard
Alvimopan is the generic ingredient in one branded drug marketed by Cubist Pharms and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

This ingredient has fifty patent family members in twenty-eight countries.

There are two drug master file entries for alvimopan. One supplier is listed for this compound.

Summary for Generic Name: alvimopan

Tradenames:1
Patents:5
Applicants:1
NDAs:1
Drug Master File Entries: see list2
Suppliers / Packaging: see list1

Pharmacology for Ingredient: alvimopan

Drug ClassOpioid Antagonist
Mechanism of ActionOpioid Antagonists

Clinical Trials for: alvimopan

Alvimopan and Ileus in PSF
Status: Active, not recruiting Condition: Ileus; Spinal Fusion

Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
Status: Completed Condition: Bowel Dysfunction; Constipation

A Study of Alvimopan for the Management of Postoperative Ileus in Participants Undergoing Radical Cystectomy
Status: Completed Condition: Postoperative Ileus

Clinical Outcomes After Bowel Resection in Patients Receiving Alvimopan Versus Patients Not Receiving Alvimopan in the Premier Perspective Database
Status: Completed Condition: Ileus

Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects
Status: Completed Condition: Cancer; Bowel Dysfunction

Clinical Evaluation Of Alvimopan (SB767905) On Constipation And Related Symptoms Associated With Opioid
Status: Terminated Condition: Cancer; Constipation

Gastrointestinal Tract Recovery in Patients Undergoing Open Ventral Hernia Repair
Status: Recruiting Condition: Ventral Hernia

Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
Status: Completed Condition: Bowel Dysfunction; Constipation

Intermountain Healthcare's Enhanced Recovery Protocol for Colon Surgery With and Without Alvimopan Use
Status: Completed Condition: Ileus

Entereg Laparoscopic Colon Resection Study
Status: Completed Condition: Laparoscopic Colonic Resection

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cubist Pharms
ENTEREG
alvimopan
CAPSULE;ORAL021775-001May 20, 2008RXYes8,112,290<disabled> <disabled>
Cubist Pharms
ENTEREG
alvimopan
CAPSULE;ORAL021775-001May 20, 2008RXYes8,645,160<disabled> <disabled>
Cubist Pharms
ENTEREG
alvimopan
CAPSULE;ORAL021775-001May 20, 2008RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: alvimopan

These historical archives are available as an add-on to one-year subscriptions

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Cubist Pharms
ENTEREG
alvimopan
CAPSULE;ORAL021775-001May 20, 20085,434,171<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: alvimopan

Country Document Number Publication Date
Canada2393141Aug 13, 2013
Japan5460771Apr 02, 2014
MexicoPA02005336Jan 28, 2003
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc